Company Overview and News

8
Magenta Therapeutics: This June IPO Should Be On Your Radar

2018-08-21 seekingalpha - 2
Ease of access to prior funding, institutional participation and strengthening of leadership team are significant green flags.
MGTA NVS GSK PFE

1
MGTA / Magenta Therapeutics, Inc. 8-K (Current Report)

2018-08-09 sec.gov - 1
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
MGTA

 
MGTA / Magenta Therapeutics, Inc. 10-Q (Quarterly Report)

2018-08-09 sec.gov
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
MGTA

5
Magenta Therapeutics: Developing Novel Treatments In Hematopoietic Stem Cell Transplants

2018-07-23 seekingalpha - 1
The current market cap of the company is about $488M which is low considering the large target markets its product candidates are addressing (reaching in multi-billions USD per year).
MGTA GSK

73
6 Speculative BioHealth Analyst Stocks That Could Rally 50% to 300%

2018-07-21 247wallst - 18
The bull market is now more than nine years old. Many investors have begun looking for new ideas and new strategies to generate income and gains, and the old strategy of buying every major market selling day has become less rewarding in 2018 versus the prior few years. It turns out that Wall Street brokerages and research shops still have many stock picks for big upside.
EIDX MGTA INNT GLMD RARX SNDX

 
MGTA / Magenta Therapeutics, Inc. null

2018-07-20 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$S(# @;V)J#3P\+TQI;F5A
MGTA

 
MGTA / Magenta Therapeutics, Inc. null

2018-07-20 sec.gov
DRSLTR May 7, 2018 Irene Paik Ada D. Sarmento Office of Healthcare and Insurance Division of Corporation Finance
MGTA

 
MGTA / Magenta Therapeutics, Inc. null

2018-07-20 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"[email protected],"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S,X M-SDO3R Q,2]%(#(X,[email protected],B]4(#,[email protected][email protected]@6R [email protected],30Y73X^#65N M9&]B:@[email protected](" @(" @(" @(" @(" @(" @#0HQ-B P(&]B:@T\/"]$96-O9&50 M87)M7!E+UA2968O5ULQ(#(@,5T^/G-T
MGTA

 
MGTA / Magenta Therapeutics, Inc. null

2018-07-20 sec.gov
CORRESP May 24, 2018 Irene Paik Ada D. Sarmento Office of Healthcare and Insurance Division of Corporation Finance
MGTA

 
MGTA / Magenta Therapeutics, Inc. null

2018-07-20 sec.gov
CORRESP CONFIDENTIAL TREATMENT REQUESTED BY MAGENTA THERAPEUTICS, INC. MGTA-0001 Goodwin Procter LLP 100 Northern Avenue
MGTA

 
MGTA / Magenta Therapeutics, Inc. null

2018-07-20 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4*)>+CS],*,2 P(&]B:@H\/"]4>7!E+UA/8FIE8W0O0V]L;W)3 M<&%C92]$979I8V5'
MGTA

 
MGTA / Magenta Therapeutics, Inc. null

2018-07-20 sec.gov
CORRESP June 8, 2018 Irene Paik Ada D. Sarmento Office of Healthcare and Insurance Division of Corporation Finance
MGTA

 
MGTA / Magenta Therapeutics, Inc. null

2018-07-20 sec.gov
CORRESP Magenta Therapeutics, Inc. 50 Hampshire Street, 8th Floor Cambridge, MA 02139 VIA EDGAR AND FACSIMILE
MGTA

 
MGTA / Magenta Therapeutics, Inc. null

2018-07-20 sec.gov
CORRESP June 18, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E.
MGTA

 
Magenta Therapeutics started at overweight with $18 stock price target at J.P. Morgan

2018-07-16 marketwatch
Your Daily Pharma Scoop: Review Of 3 Stocks From The Biotech Boom IPO Week (18 - 22 June)
MGTA

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 55910K108